VKTX
Viking Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.90B
P/E Ratio
—
EPS
$-3.19
Beta
0.82
52W High
$43.15
52W Low
$21.21
50-Day MA
$32.06
200-Day MA
$32.26
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.03
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -47.30% |
| Return on Assets | -30.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.57 |
| Price-to-Book | 6.29 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -71.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $115.89M |
| Float | $112.74M |
| % Insiders | 2.81% |
| % Institutions | 62.86% |
Analyst Ratings
Consensus ($92.72 target)
5
Strong Buy12
Buy2
HoldData last updated: 4/9/2026